Commission Regulation (EC) No 1876/2004 of 28 October 2004 amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines

COMMISSION REGULATION (EC) No 1876/2004

of 28 October 2004

amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines[(1)], and in particular Article 4(8) thereof,

Whereas:

(1) The Commission has received applications under Article 4 of Regulation (EC) No 953/2003 with respect to certain pharmaceutical products.

(2) The Commission has determined that the applications received fulfil the requirements set out in Regulation (EC) No 953/2003 in accordance with the procedure laid down in Article 5(2) of that Regulation.

(3) The applicants have been informed of the Commission decision to accept their applications.

(4) It is therefore necessary to add the products concerned to Annex I to Regulation (EC) No 953/2003,

HAS ADOPTED THIS REGULATION:

Article 1

The products and other details mentioned in the Annex to this Regulation shall be added to Annex I to Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines.

Article 2

This regulation enters into force on the day following its publication in the *Official Journal of the European Union*.

It shall be binding in its entirety and directly applicable in all Member States.

Changes to legislation: Commission Regulation (EC) No 1876/2004 is up to date with all changes known to be in force on or before 01 March 2022. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

Done at Brussels, 28 October 2004.

For the Commission

Pascal LAMY

Member of the Commission

***Changes to legislation:** Commission Regulation (EC) No 1876/2004 is up to date with all changes known to be in force on or before 01 March 2022. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

ANNEX

Product	Manufacturer/Country of exporter	Country of destination	Distinctive features	Date of approval	CN/TARIC code[a]
‘**TRIZIVIR 750 mg × 60**	Glaxo Smith Kline, GSK House, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom	Afghanistan Angola Armenia Azerbaijan Bangladesh Benin Bhutan Botswana Burkina Faso Burundi Cambodia Cameroon Cape Verde Central African Republic Chad Comoros Congo Côte d’Ivoire Djibouti DR Congo East Timor Equatorial Guinea Eritrea Ethiopia Gambia Ghana Guinea Guinea Bissau Haiti Honduras India Indonesia Kenya Kiribati Korea (Dem Rep) Kyrgyz Republic Lao People’s DR Lesotho Liberia Madagascar	Distinctive access pack — trilingual text	19.4.2004	3004 90 19
EPIVIR 150 mg × 60	Glaxo Smith Kline, GSK House, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom		Distinctive access pack — trilingual text	19.4.2004	3004 90 19
RETROVIR 250 mg × 40	Glaxo Smith Kline, GSK House, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom		General export pack (blue) not used in EU French hospital pack — Francophone markets	19.4.2004	3004 90 19
RETROVIR 300 mg × 60	Glaxo Smith Kline, GSK House, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom		General export pack (blue) not used in EU French hospital pack — Francophone markets	19.4.2004	3004 90 19
RETROVIR 100 mg × 100	Glaxo Smith Kline, GSK House, 980 Great West Road,		General export pack (blue) not used in EU	19.4.2004	3004 90 19

a Only if applicable.’